With Over 400 million chronic patientsIndia is one of the world’s largest medicine market. But when most of the fast e-pharos, the availability remains a real challenge. Trase The different route: helping the patient’s diverting low costs, betting is now paid new funds at four times before.
Startup age six years has returned $ 85 million in the new half of the secondary and $ 20 million in a secder and $ 20 million in the secondary fund by accel, as well as participation of the summit of XV partners. TechCrunch First reported in accel speech Back again last year. Investors are existing in Westbridge Capital and efforts, well involved.
Fresh round has increased the value of Truememed ‘with more than $ 400 million, from $ 110 million in the last two years.
Etoned in 2019, the truemeds entered the market at a time when India’s online pharmacy room has been busy with a major player who offers a steep discount on the correct line. But some of these companies are struggling to support early momentum – Phameasy supported by farmeasy, for example, see value drop out of the summit of $ 5.6 billion up to $ 600 millionwhile 1mg obtained by Digital Tatapart of the duty group. Instead of the focusing of the competition, the Truemeds’ chooses to focus on the relative cegment: General drugs.
“There’s no way to educate the user who can have more affordable options if you cannot use the drug,” Tranimeded co-fofters nayysia (drawn) in the interview. “That’s where we feel there is no one who has the value of the chain, and we can blow it.”
The alternative is based on Mumbai to be consumers for consumers for the necessary drugs. Finally helps consumer saves money, public medicines are usually higher than the brand version due to the cost of precious.
TroMemed said that different approaches were paid, with more than 66% revenue of year over 66% more than 66% of the year for the last 26%) in last financial year. Startup says that it remains more than 15% of the income after 12 months and is currently an average of 500,000 customers per month, with 3 million customers. In addition, saying is more than 20,000 postal codes around the country, with more than 75% of customers who come from cities and more than Tier-2 cities and more of the cities and more than.
TechCrunch Events
San Francisco
|
October 27, 2025
However, you teach customers about alternatives to the drugs that have been given – and convinced her switch from brand medicines for generic – remaining a challenge.
“Because you get the price according to the brand’s price given, and if you will see a cheaper price, you want to know why less,” Nayyar who told TechCrunch.
Increase discounts during the cutting competitor
When e-pharmacies today hunt a savings, the playful toy of the sector is different. Online pharmacy in India used to offer discounts up to 25% to attract customers. However, he said that 20% later – the new average – like the most burned cash to obtain a new customer and pivot for faster posts as the main difference.
Meanwhile, TrueDemed has been away in different directions, increasing an average discount of 29% to 32% in the past 12 months. For the average user that switch brands on platform, Tabu comes 47% on the drug, says the company.
It comes from the correct protection with the Farma company, where the start of the technology to provide better preservation visibility, helping them to design more efficient for the coming quarter.
Startup also depends on your own logistics in some major cities that work and use the low logistics partners for the rest.
“We believe that for the model of four hours we are more likely from chronic patient perspective,” Nayyar said. “You can do more planned by the way, but we want to do it effectively, and more discounts for the last user instead of (focus) are the fastest for the problem.”
Next up: customization of ai-powered and diagnostic doorstep
As transreemed should convince the customers to choose a generic through the brand drugs, so through deeper consultation. Has conducted 10-12 million consult per year. Startup has developed a algorithm for many years that appears to be a variety of parameters to advise alternatives to the brand-provided drugs. It considers the nuance such as whether the drug is covered with sugar if the young patient is patient, where it is produced, and what plant is the GMP-certification. Startup also has a Chathbot to solve some user’s quick questions.
More on the way. The company plans to develop ai-based system that manages the conversation based on the behavior of customers and previous interactions with the general alternative. It also opens the Bengaluru office when it comes to at least 20% of the capital for techniques and product development products.
In addition to medicines, TrueeMed is a plotting to enter diagnostics through the national pathological lesson, design a tier-2 test service in some to four months.
“The main mission remains the same, which makes health affordable for the end user,” the founder said. “Start with drugs. Now the model is defined, we will remain scaling. Different, we also want to see what the diagnostic is the most common test.”
Startup also plans to improve the center of the 300% – from 19 now – over the next 12 months, directing the deeper in the market.
Before this round, Trenemed raise $ 50 million and still there was 30-35% of the capital in the bank, said Nayyar.
Startup has a labor of 2,800 people, with 250 based on Mumbai office.